GlaxoSmithKline $GSK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS121
PHASE 3 / 2-365
RECRUITING72
READOUTS ≤12 MONTHS31
READOUT SLIPPED >6 MO37%
Delay Index: of 76 active trials registered more than a year ago, 28 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.0 months). See all sponsors →
Open GlaxoSmithKline on the live radar map → 📅 $GSK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| RSVPreF3 OA investigational vaccine NCT04732871 |
P3 | Active, not recruiting | Respiratory Syncytial Virus Infections | 1720 | 2022-06-06 |
| DREAMM-3 NCT04162210 |
P3 | Active, not recruiting | Multiple Myeloma | 325 | 2022-09-12 (+12 mo) |
| Belimumab NCT04179032 |
P2 | Active, not recruiting | Systemic Lupus Erythematosus | 25 | 2023-01-16 (-2 mo) |
| DREAMM 7 NCT04246047 |
P3 | Active, not recruiting | Multiple Myeloma | 494 | 2023-10-02 (+9 mo) |
| DREAMM 8 NCT04484623 |
P3 | Active, not recruiting | Multiple Myeloma | 302 | 2024-01-29 (+20 mo) |
| DREAMM 7 NCT06868654 |
P3 | Active, not recruiting | Multiple Myeloma | 72 | 2024-04-03 |
| DREAMM 7 NCT06868667 |
P3 | Active, not recruiting | Multiple Myeloma | 24 | 2024-04-03 |
| DREAMM 8 NCT06956170 |
P3 | Active, not recruiting | Multiple Myeloma | 21 | 2024-05-27 |
| ZEST NCT04915755 |
P3 | Active, not recruiting | Neoplasms, Breast | 40 | 2024-06-28 (-7 mo) |
| Belantamab mafodotin NCT07150104 |
P1/2 | Active, not recruiting | Multiple Myeloma | 14 | 2025-04-17 |
| Belantamab mafodotin NCT07217184 |
P1/2 | Active, not recruiting | Multiple Myeloma | 30 | 2025-04-17 |
| DREAMM 5 NCT04126200 |
P1/2 | Active, not recruiting | Multiple Myeloma | 208 | 2025-04-17 (-13 mo) |
| Belantamab mafodotin NCT07084896 |
P1/2 | Active, not recruiting | Multiple Myeloma | 106 | 2025-04-17 |
| Belantamab mafodotin NCT07217119 |
P1/2 | Active, not recruiting | Multiple Myeloma | 25 | 2025-04-17 |
| Belantamab mafodotin NCT07150091 |
P1/2 | Active, not recruiting | Multiple Myeloma | 20 | 2025-04-17 |
| COSTAR Lung NCT04655976 |
P2/3 | Active, not recruiting | Lung Cancer, Non-Small Cell | 758 | 2025-06-05 (+9 mo) |
| PED-HZ/su NCT04006808 |
P1/2 | Recruiting | Herpes Zoster | 184 | 2026-05-01 (+24 mo) |
| SYLVER NCT06710847 |
P1/2 | Active, not recruiting | Neoplasms, Colorectal; Solid Tumor | 14 | 2026-06-22 (-8 mo) |
| Dostarlimab NCT06472076 |
P3 | Active, not recruiting | Lung Cancer, Non-Small Cell | 88 | 2026-06-30 (-27 mo) |
| GSK4524101 NCT06077877 |
P1/2 | Active, not recruiting | Neoplasms | 42 | 2026-06-30 (+12 mo) |
| GSK5784283 NCT06748053 |
P2 | Active, not recruiting | Asthma | 307 | 2026-07-14 |
| RSVPreF3 OA vaccine NCT07220109 |
P3 | Active, not recruiting | Respiratory Syncytial Virus Infections | 750 | 2026-07-20 |
| Candidate varicella vaccine NCT06855160 |
P3 | Recruiting | Chickenpox | 911 | 2026-09-10 |
| Dostarlimab NCT06062420 |
P2 | Active, not recruiting | Neoplasms, Head and Neck | 316 | 2026-09-10 (+12 mo) |
| OCEAN NCT05263934 |
P3 | Active, not recruiting | Eosinophilic Granulomatosis With Polyangiitis | 163 | 2026-09-29 (+12 mo) |
| RSV OA=ADJ=012 NCT06534892 |
P3 | Active, not recruiting | Respiratory Syncytial Virus Infections | 10212 | 2026-09-30 |
| LLSAT NCT04167358 |
P3 | Active, not recruiting | Cholestasis | 242 | 2026-09-30 (+27 mo) |
| Cobolimab NCT06521567 |
P1/2 | Active, not recruiting | Melanoma; Hodgkin Lymphoma | 83 | 2026-10-13 (-21 mo) |
| Pembrolizumab NCT05565378 |
P2 | Active, not recruiting | Lung Cancer, Non-Small Cell | 351 | 2026-10-26 (+24 mo) |
| AZUR-1 NCT05723562 |
P2 | Active, not recruiting | Neoplasms, Rectal | 154 | 2026-11-02 (+11 mo) |
| Investigational varicella vaccine NCT06693895 |
P3 | Recruiting | Chickenpox | 750 | 2026-11-23 (+4 mo) |
| dTpa NCT07596199 |
P3 | Active, not recruiting | Diphtheria-Tetanus-acellular Pertussis Vaccines | 102 | 2026-11-23 |
| AZUR-4 NCT06567782 |
P2 | Recruiting | Neoplasms, Colon | 120 | 2026-11-23 (-21 mo) |
| Momelotinib NCT03441113 |
P2 | Active, not recruiting | Primary Myelofibrosis | 237 | 2026-12-11 (+78 mo) |
| Investigational varicella vaccine NCT06806137 |
P3 | Recruiting | Chickenpox | 600 | 2026-12-14 (+1 mo) |
| RUBY-J NCT06317311 |
P2 | Active, not recruiting | Carcinoma | 41 | 2026-12-14 (+5 mo) |
| Investigational varicella vaccine_Lot 1 NCT06740630 |
P3 | Recruiting | Chickenpox | 1840 | 2026-12-25 |
| Niraparib NCT04641247 |
P2 | Recruiting | Ovarian Neoplasms; Breast Neoplasms | 37 | 2026-12-28 (+13 mo) |
| HFA-152a NCT07645248 |
P3 | Recruiting | Asthma | 110 | 2026-12-28 |
| Adjuvanted RSVPreF3 vaccine NCT07092865 |
P2 | Active, not recruiting | Respiratory Syncytial Virus Infections | 168 | 2027-01-12 |
| FF/UMEC/VI NCT05757102 |
P3 | Active, not recruiting | Asthma | 138 | 2027-01-26 (+28 mo) |
| GLIDE NCT07671001 |
P3 | Recruiting | Asthma | 34 | 2027-03-01 |
| BALANCE NCT07519395 |
P2 | Recruiting | Irritable Bowel Syndrome | 420 | 2027-03-09 |
| MenABCWY vaccine NCT05087056 |
P2 | Active, not recruiting | Meningitis, Meningococcal | 305 | 2027-03-10 (+9 mo) |
| ODYSSEY NCT06517875 |
P2 | Recruiting | Primary Myelofibrosis; Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | 68 | 2027-03-16 (+7 mo) |
| B-Focus NCT06497504 |
P2 | Active, not recruiting | Hepatitis B | 153 | 2027-04-22 (+3 mo) |
| RTS,S/AS01E vaccine NCT07036159 |
P2 | Recruiting | Malaria | 238 | 2027-04-23 |
| GSK3862995B NCT07201051 |
P2 | Recruiting | Bronchiectasis | 363 | 2027-05-04 (+2 mo) |
| Tafenoquine NCT06666491 |
P3 | Recruiting | Malaria, Vivax | 324 | 2027-05-14 (+13 mo) |
| Candidate UTI vaccine low dose formulation 1 NCT06702449 |
P1/2 | Recruiting | Urinary Tract Infections | 448 | 2027-05-31 (-2 mo) |
| B-UNITED NCT06537414 |
P2 | Active, not recruiting | Chronic Hepatitis B Virus Infection; Hepatitis B | 283 | 2027-05-31 (-7 mo) |
| Mo-Rez NCT06796907 |
P1/2 | Recruiting | Tumours, Gynecological | 305 | 2027-06-21 (+5 mo) |
| mRNA Seasonal Flu vaccine NCT07851246 |
P3 | Recruiting | Influenza, Human | 3000 | 2027-07-09 |
| MIDAS NCT06847867 |
P2 | Recruiting | Myelodysplastic Syndromes | 80 | 2027-07-14 (+3 mo) |
| HZ/su vaccine NCT05371080 |
P3 | Active, not recruiting | Herpes Zoster | 3038 | 2027-08-23 |
| CALM-2 NCT07650084 |
P3 | Recruiting | Refractory Chronic Cough | 75 | 2027-08-27 |
| GSK3772701 600 mg NCT07545681 |
P2 | Recruiting | Malaria, Falciparum | 70 | 2027-10-08 |
| China AZUR-1 NCT06640049 |
P2 | Active, not recruiting | Neoplasms, Rectal | 23 | 2027-10-24 (-14 mo) |
| GSK5458514 NCT06990880 |
P1/2 | Recruiting | Neoplasms, Prostate | 85 | 2027-10-26 |
| DESTINY NCT05334368 |
P3 | Active, not recruiting | Hypereosinophilic Syndrome | 110 | 2027-10-29 (+30 mo) |
| Ris-Rez NCT07602777 |
P1/2 | Recruiting | Sarcoma | 64 | 2027-11-05 |
| Risvutatug rezetecan (Ris-Rez) NCT07099898 |
P3 | Recruiting | Neoplasms, Lung | 420 | 2027-11-05 (+14 mo) |
| STARLIGHT NCT06613698 |
P2 | Recruiting | Liver Diseases, Alcoholic | 350 | 2027-11-26 (+12 mo) |
| Velzatinib NCT07689201 |
P2 | Recruiting | Gastrointestinal Neoplasms | 24 | 2027-11-29 |
| Depemokimab NCT06979323 |
P3 | Recruiting | Asthma | 150 | 2028-01-05 (-1 mo) |
| MMRVNS NCT07406360 |
P3 | Recruiting | Measles; Measles-Mumps-Rubella+Chickenpox Vaccine | 1209 | 2028-02-28 |
| Mocertatug rezetecan NCT07286331 |
P3 | Recruiting | Neoplasms, Endometrial | 600 | 2028-02-29 |
| GSK5471713 NCT07332455 |
P1/2 | Recruiting | Neoplasms, Prostate | 54 | 2028-03-24 |
| ZENITH-2 NCT07221188 |
P3 | Recruiting | Non-alcoholic Fatty Liver Disease | 1250 | 2028-03-24 |
| ZENITH-1 NCT07221227 |
P3 | Recruiting | Non-alcoholic Fatty Liver Disease | 1200 | 2028-03-29 |
| Low dose of iNTS-TCV NCT07286370 |
P2 | Recruiting | Salmonella Infections | 537 | 2028-04-27 |
| IDRX-42 NCT07218926 |
P3 | Recruiting | Gastrointestinal Neoplasms | 450 | 2028-05-30 (+1 mo) |
| mRNA Seasonal Flu vaccine NCT07805707 |
P3 | Recruiting | Influenza, Human | 54000 | 2028-06-09 |
| MMRVNS 20-002 NCT07742644 |
P3 | Not yet recruiting | Measles; Mumps | 1860 | 2028-06-27 |
| JADE NCT06256588 |
P3 | Recruiting | Neoplasms, Head and Neck | 864 | 2028-06-30 |
| Efimosfermin NCT06920043 |
P2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease | 42 | 2028-07-03 (+8 mo) |
| DynaMMic-1 NCT05714839 |
P1/2 | Recruiting | Multiple Myeloma | 123 | 2028-08-03 (+13 mo) |
| ALLSTAR NCT07791043 |
P2 | Recruiting | Liver Diseases, Alcoholic | 274 | 2028-08-11 |
| GSK4527226 NCT07105709 |
P2 | Recruiting | Alzheimer's Disease | 220 | 2028-09-15 |
| GSK5460025 NCT07213609 |
P1/2 | Recruiting | Neoplasms, Colorectal; Neoplasms | 47 | 2028-09-28 |
| H06_04TP NCT07320716 |
P2 | Recruiting | Diarrhoea | 179 | 2028-10-16 |
| Linerixibat NCT07860710 |
P3 | Not yet recruiting | Pruritus | 40 | 2028-10-23 |
| ATLAS NCT07569081 |
P2/3 | Not yet recruiting | VEXAS Syndrome | 136 | 2028-12-06 |
| ENDURA-2 NCT06961214 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 961 | 2028-12-13 (-8 mo) |
| ENDURA-1 NCT06959095 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 981 | 2028-12-13 (-8 mo) |
| Risvutatug Rezetecan NCT06885034 |
P1/2 | Recruiting | Gastrointestinal Neoplasms | 346 | 2029-01-09 (+25 mo) |
| B-Sure NCT04954859 |
P2 | Active, not recruiting | Hepatitis B | 366 | 2029-01-24 (+78 mo) |
| GSK5784283 NCT07780643 |
P3 | Recruiting | Asthma | 514 | 2029-02-15 |
| DREAMM-16 NCT07614360 |
P2 | Not yet recruiting | Multiple Myeloma | 150 | 2029-02-28 |
| PERSISTCRSwNP1 NCT07782970 |
P3 | Recruiting | Nasal Polyps | 218 | 2029-03-06 |
| PERSISTCRSwNP2 NCT07782957 |
P3 | Recruiting | Nasal Polyps | 218 | 2029-03-06 |
| ALARMONY NCT07915791 |
P2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 279 | 2029-03-07 |
| Dostarlimab NCT05855200 |
P3 | Recruiting | Colonic Neoplasms; Neoplasms, Colon | 892 | 2029-03-19 (+3 mo) |
| VIGILANT NCT07177339 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 1196 | 2029-04-02 (-7 mo) |
| RSV/hMPV_V low dose vaccine NCT07628049 |
P1/2 | Recruiting | Respiratory Syncytial Virus Infections+Metapneumovirus | 1456 | 2029-04-05 |
| Adjuvanted RZV vaccine NCT07712380 |
P2 | Not yet recruiting | Cardiovascular Disease | 450 | 2029-05-02 |
| GSK5784283 NCT07782996 |
P3 | Recruiting | Asthma | 370 | 2029-05-04 |
| Risvutatug rezetecan NCT07602855 |
P1/2 | Recruiting | Neoplasms, Lung | 184 | 2029-06-22 |
| GSK5784283 NCT07780656 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 624 | 2029-07-20 |
| GSK5784283 NCT07780669 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 624 | 2029-07-20 |
| Mocertatug rezetecan NCT07684599 |
P3 | Recruiting | Neoplasms, Endometrial | 610 | 2029-07-23 |
| BEconneCTD-ILD NCT06572384 |
P3 | Recruiting | Lung Diseases, Interstitial | 440 | 2029-08-30 (+10 mo) |
| BLISSc-ILD NCT05878717 |
P2/3 | Recruiting | Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic | 300 | 2029-08-30 (+34 mo) |
| Mocertatug rezetecan NCT07694427 |
P3 | Recruiting | Ovarian Neoplasms | 720 | 2029-09-06 |
| Risvutatug rezetecan (Ris-Rez) NCT07802704 |
P3 | Recruiting | Neoplasms, Prostate | 684 | 2029-12-05 |
| GSK5926371 NCT07607925 |
P1/2 | Recruiting | Lymphoma, Non-Hodgkin | 49 | 2030-01-10 |
| DuraSTAR NCT07740720 |
P3 | Not yet recruiting | Neoplasms, Rectal | 100 | 2030-03-13 |
| Dostarlimab NCT07108270 |
P2 | Recruiting | Neoplasms, Endometrial | 30 | 2030-03-31 |
| Mocertatug rezetecan (Mo-Rez) NCT07684612 |
P3 | Recruiting | Ovarian Neoplasms | 690 | 2030-05-21 |
| Mocertatug rezetecan NCT07286266 |
P3 | Recruiting | Ovarian Neoplasms | 450 | 2030-07-22 |
| Belantamab mafodotin NCT07227311 |
P2 | Recruiting | Multiple Myeloma | 200 | 2030-08-30 (+2 mo) |
| MODIFY NCT07456033 |
P3 | Recruiting | Asthma | 456 | 2030-09-23 |
| Belimumab NCT06716606 |
P3 | Recruiting | Connective Tissue Diseases | 514 | 2030-09-27 (+27 mo) |
| NEBULA-2 NCT07704892 |
P3 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis | 380 | 2030-10-16 |
| SAPPHIRE NCT07860450 |
P3 | Not yet recruiting | Endometrial Carcinoma; Neoplasms, Endometrial | 378 | 2030-11-05 |
| Velzatinib NCT07843641 |
P2 | Not yet recruiting | Gastrointestinal Neoplasms | 72 | 2031-01-31 |
| DREAMM-10 NCT06679101 |
P3 | Recruiting | Multiple Myeloma; Newly Diagnosed Multiple Myeloma | 520 | 2031-04-28 (-8 mo) |
| Velzatinib NCT07585266 |
P3 | Recruiting | Gastrointestinal Stromal Neoplasms | 800 | 2032-08-30 |
| RZV vaccine NCT07872046 |
P3 | Not yet recruiting | Cardiovascular Disease | 16390 | 2032-11-25 |
| ALANIS NCT07224672 |
P2 | Recruiting | Amyloidosis | 60 | 2033-01-12 (+68 mo) |
| NEBULA-1 NCT07701993 |
P3 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis | 1740 | 2033-06-23 |